Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 470,098	$ 393,772	[1]
Marketable securities	218,466	393,743	[1]
Investment in equity securities	27,141	49,148	[1]
Receivable from licensing and collaboration agreements	22,821	19,749	[1]
Prepaid expenses and other current assets	32,754	32,446	[1]
Total current assets	771,280	888,858	[1]
Property and equipment, net	16,873	30,066	[1]
Operating lease right-of-use assets	12,850	15,907	[1]
Intangible assets, net	29,908	44,934	[1]
Other assets	31,322	33,027	[1]
Total assets	862,233	1,012,792	[1]
Current liabilities:
Accounts payable	8,793	11,884	[1]
Accrued compensation and benefits	32,609	37,041	[1]
Accrued research and development liabilities	50,091	44,138	[1]
Accrued professional services	6,183	6,786	[1]
Operating lease liabilities, current portion	4,310	4,938	[1]
Deferred revenue, current portion	7,190
Other accrued liabilities	31,984	30,282	[1]
Total current liabilities	141,160	135,069	[1]
Term loan, net	418,353	430,752	[1]
Operating lease liabilities, net of current portion	14,276	17,428	[1]
Other long-term liabilities	28,631	22,069	[1]
Total liabilities	1,877,246	1,878,371	[1]
Commitments and contingencies (Note 9)
Redeemable convertible noncontrolling interests	(1,499)	1,423
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 154,434,958 shares issued and 148,243,197 shares outstanding as of June 30, 2022, 153,535,084 shares issued and 147,343,323 shares outstanding as of December 31, 2021	154	154	[1]
Treasury stock, at cost; 6,191,761 shares as of June 30, 2022 and December 31, 2021	(275,000)	(275,000)	[1]
Additional paid-in capital	892,960	841,530	[1]
Accumulated other comprehensive loss	(427)	(132)	[1]
Accumulated deficit	(1,643,219)	(1,436,966)	[1]
Total BridgeBio stockholders' deficit	(1,025,532)	(870,414)	[1]
Noncontrolling interests	12,018	3,412	[1]
Total stockholders' deficit	(1,013,514)	(867,002)	[1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	862,233	1,012,792	[1]
2029 Notes
Current liabilities:
Notes, net	734,047	733,119	[1]
2027 Notes
Current liabilities:
Notes, net	$ 540,779	$ 539,934	[1]

[1] The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.

[2] The consolidated balances as of December 31, 2021 and 2020 are derived from the audited consolidated financial statements as of those dates.